Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and advanced metastatic MCC frequently responds to PD...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Topalian, Suzanne L., Bhatia, Shailender, Amin, Asim, Kudchadkar, Ragini R., Sharfman, William H., Lebbé, Celeste, Delord, Jean-Pierre, Dunn, Lara A., Shinohara, Michi M., Kulikauskas, Rima, Chung, Christine H., Martens, Uwe M., Ferris, Robert L., Stein, Julie E., Engle, Elizabeth L., Devriese, Lot A., Lao, Christopher D., Gu, Junchen, Li, Bin, Chen, Tian, Barrows, Adam, Horvath, Andrea, Taube, Janis M., Nghiem, Paul
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2020
主題:
Rapid Communications
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392746/
https://ncbi.nlm.nih.gov/pubmed/32324435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00201
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料